CD8A and cancer: The identification of novel immune checkpoints such as PD-1, PD-L1, CTLA-4, TIM3, and others by inciting or suppressing cytotoxic CD8+ T lymphocytes, regulatory T cells, NK cells, and others has provided new ideas for the treatment of malignant tumors [4–6].